The targeted delivery of IL17 to the mouse tumor neo-vasculature enhances angiogenesis but does not reduce tumor growth rate

Angiogenesis. 2012 Mar;15(1):165-9. doi: 10.1007/s10456-011-9239-8. Epub 2011 Nov 4.

Abstract

There has been a long controversy as to whether interleukin-17 (IL17) has an impact on tumor growth. In order to assess whether IL17 may affect tumor growth, it would be convenient to achieve high levels of this pro-inflammatory cytokine at the tumor neo-vasculature, since IL17 is known to promote angiogenesis. Here, we have generated and tested in vivo a fusion protein, consisting of the F8 antibody (specific to the alternatively spliced EDA domain of fibronectin, a marker of angiogenesis) and of murine IL17 (mIL17). The resulting immunocytokine (termed F8-mIL17) was shown to selectively localize at the tumor neo-vasculature and to vigorously promote tumor angiogenesis, without however reducing or enhancing tumor growth rate both in immunocompetent and in immunodeficient mice.

MeSH terms

  • Animals
  • Antibodies / immunology
  • Cell Line
  • Cell Proliferation / drug effects
  • Cloning, Molecular
  • Drug Delivery Systems / methods*
  • Interleukin-17 / pharmacology
  • Interleukin-17 / therapeutic use*
  • Mice
  • Neoplasms / blood supply*
  • Neoplasms / drug therapy*
  • Neoplasms / pathology
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Recombinant Fusion Proteins / pharmacology
  • Recombinant Fusion Proteins / therapeutic use
  • Subcutaneous Tissue / drug effects
  • Subcutaneous Tissue / pathology

Substances

  • Antibodies
  • Interleukin-17
  • Recombinant Fusion Proteins